BSE - Delayed Quote INR
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.BO)
243.55
+4.35
+(1.82%)
At close: April 25 at 3:44:11 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
2,536,420
2,087,020
2,367,140
2,175,840
1,879,456
Cost of Revenue
925,380
801,330
925,140
892,820
809,340
Gross Profit
1,611,040
1,285,690
1,442,000
1,283,020
1,070,116
Operating Expense
1,220,440
1,069,020
1,098,700
1,037,570
882,252
Operating Income
390,600
216,670
343,300
245,450
187,864
Net Non Operating Interest Income Expense
76,760
77,780
30,150
12,610
24,789
Pretax Income
656,870
298,690
348,080
266,420
218,723
Tax Provision
133,600
74,060
80,870
77,870
48,140
Net Income Common Stockholders
523,270
224,630
267,210
188,550
170,583
Diluted NI Available to Com Stockholders
523,270
224,630
267,210
188,550
170,583
Basic EPS
9.54
3.40
4.08
2.88
2.60
Diluted EPS
9.50
3.38
4.08
2.88
2.60
Basic Average Shares
66,364.91
66,123.63
65,495
65,495
65,495
Diluted Average Shares
66,364.91
66,299.17
65,495
65,495
65,495
Rent Expense Supplemental
--
9,130
18,310
24,770
22,687
Total Expenses
2,145,820
1,870,350
2,023,840
1,930,390
1,691,592
Net Income from Continuing & Discontinued Operation
523,270
224,630
267,210
188,550
170,583
Normalized Income
364,752.34
224,630
290,401.87
191,897.50
168,629.34
Interest Income
--
85,920
34,280
15,460
29,924
Interest Expense
8,790
7,770
2,780
2,610
4,275
Net Interest Income
76,760
77,780
30,150
12,610
24,789
EBIT
665,660
306,460
350,860
269,030
222,998
EBITDA
727,950
323,090
362,610
284,290
233,858
Reconciled Cost of Revenue
925,380
801,330
925,140
892,820
809,340
Reconciled Depreciation
62,290
16,630
11,750
15,260
10,860
Net Income from Continuing Operation Net Minority Interest
523,270
224,630
267,210
188,550
170,583
Total Unusual Items Excluding Goodwill
198,990
--
-29,820
-4,730
2,505
Total Unusual Items
198,990
--
-29,520
-4,730
2,505
Normalized EBITDA
528,960
323,090
392,130
289,020
231,353
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
40,472.34
--
-6,928.13
-1,382.50
551.34
3/31/2021 - 11/27/2001
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
WINDLAS.BO Windlas Biotech Limited
998.30
-2.30%
BAFNAPH.NS Bafna Pharmaceuticals Limited
80.40
+4.52%
JBCHEPHARM.BO J. B. Chemicals & Pharmaceuticals Limited
1,576.05
-2.10%
SOLARA.BO Solara Active Pharma Sciences Limited
509.40
-4.60%
SAKAR.NS Sakar Healthcare Limited
291.03
-2.80%
WOCKPHARMA.BO Wockhardt Limited
1,396.35
-4.82%
AARTIDRUGS.NS Aarti Drugs Limited
350.80
-4.11%
AARTIPHARM.NS Aarti Pharmalabs Limited
735.15
-2.49%
MOREPENLAB.NS Morepen Laboratories Limited
58.82
-5.46%
MANKIND.NS Mankind Pharma Limited
2,557.50
-1.60%